MS Briefs

Out-of-Pocket Costs for MS Drugs Rose Significantly

Publish date: September 12, 2019

 

Key clinical point : Prices of self-administered disease-modifying therapies for multiple sclerosis increased significantly from 2006 to 2016.

Major finding : Patients’ out-of-pocket costs increased by a factor of 7.2 during this period.

Study details : A cohort study of Medicare claims data from 2006 to 2016.

Disclosures: The Myers Family Foundation and the National Heart, Lung, and Blood Institute funded this research. Several authors are employees of health insurance companies such as the UPMC Health Plan Insurance Services Division and Humana. One author received personal fees from Pfizer that were unrelated to this study.

Citation: San-Juan-Rodriguez A et al. JAMA Neurol. 2019 Aug 26. doi: 10.1001/jamaneurol.2019.2711 ; Hartung DM and Bourdette D. JAMA Neurol. 2019 Aug 26. doi: 10.1001/jamaneurol.2019.2445 .

Recommended Reading

Interview with Andrew Pachner, MD, about the molecular processes of multiple sclerosis
ICYMI Multiple Sclerosis
Neutrophils May Decline in Patients on Fingolimod
ICYMI Multiple Sclerosis
Black Holes Associated With Impaired Cognition in MS
ICYMI Multiple Sclerosis
Vaccination Not Associated With Increased Risk of MS
ICYMI Multiple Sclerosis
Serum neurofilament light chain level may indicate MS disease activity
ICYMI Multiple Sclerosis
Pediatric-Onset MS May Slow Information Processing in Adulthood
ICYMI Multiple Sclerosis
Patients With MS Who Consider Marijuana Use More Likely to Engage in Risky Behaviors
ICYMI Multiple Sclerosis
Switching From Interferon Beta-1a to Alemtuzumab Improves MS Outcomes
ICYMI Multiple Sclerosis
Interview with Andrew Solomon, MD, on diagnosing multiple sclerosis
ICYMI Multiple Sclerosis
Neurologists need not discourage breastfeeding in women with MS
ICYMI Multiple Sclerosis